Autolus Therapeutics (NASDAQ:AUTL) Hits New 52-Week Low - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low on Monday when its share price fell to $1.86, marking a significant drop. The stock later traded at $1.88, with a total trading volume of 258,277 shares. This follows a previous close of $1.95.

Analyst Ratings and Insights

Recent Analyst Upgrades and Downgrades

Several research analysts have provided insights on Autolus Therapeutics. Redburn Atlantic recently upgraded the company's rating from "neutral" to "buy" and set a price target of $13.00 as of November 15. Additionally, Needham & Company maintained a "buy" rating with a price target of $10.00 on January 13. Furthermore, The Goldman Sachs Group also upgraded their recommendation from "neutral" to "buy" and adjusted their target price from $7.00 to $7.60 on November 18. Overall, five analysts have rated Autolus as a buy. According to MarketBeat.com, the company holds an average rating of "Buy" with a consensus target price of $10.40.

Autolus Therapeutics Summary

Market Performance

As of now, the stock has declined by 2.3%. The 50-day moving average price stands at $2.23, while the 200-day moving average is at $3.18. Autolus Therapeutics has a market capitalization of $506.90 million, with a negative price-to-earnings ratio of -1.57 and a beta of 2.02, suggesting increased volatility.

Institutional Holdings and Changes

Recently, various hedge funds have adjusted their stakes in Autolus Therapeutics. China Universal Asset Management Co. Ltd. increased its holdings by 63.8% during the third quarter, now owning 38,393 shares valued at $139,000 after acquiring an additional 14,959 shares. Likewise, Privium Fund Management B.V. raised its stake by 15.6%, with 185,639 shares valued at $674,000 after an additional purchase of 25,000 shares. Other institutional investors, such as GSA Capital Partners LLP and HealthInvest Partners AB, have also significantly increased their investments. Currently, institutional investors and hedge funds hold approximately 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc is a clinical-stage biopharmaceutical firm focused on developing T cell therapies for cancer and autoimmune diseases. Their clinical programs include notable candidates such as obecabtagene autoleucel (AUTO1), designed to treat adult acute lymphoblastic leukemia, and AUTO1/22, aimed at pediatric patients. Other investigational therapies include AUTO4 for peripheral T-cell lymphoma and AUTO6NG for neuroblastoma.

For those interested in stock trends, Autolus Therapeutics certainly presents an interesting option given the varying analyst ratings and institutional interests. However, investors should conduct further research before making any decisions.

Stock, Investment, Market